echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Yale Cancer Center study confirms treatment for aggressive bladder cancer

    Yale Cancer Center study confirms treatment for aggressive bladder cancer

    • Last Update: 2022-03-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Image: ASCO GU 2022

    Source: Yale Cancer Center

    A new study led by Yale Cancer Center researchers finds that enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin chemotherapy


    "The findings are significant and encouraging because of the low survival rates for muscle-invasive bladder cancer


    In this trial, investigators recruited patients diagnosed with MIBC who were not candidates for cisplatin-based chemotherapy but who were candidates for surgery


    Petrylak added: "We look forward to conducting a Phase 3 study to further evaluate the efficacy of enfortumab vedotin



     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.